GlaxoSmithKline’s Votrient Recommended For Renal Cell Carcinoma in Draft NICE Appraisal
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K. will receive a rebate if Votrient does not match Pfizer's Sutent in a current head-to-head trial.